REG - Haleon PLC - Holding(s) in Company

HALEONAnnouncement

21/03/2025 18:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250321:nRSU7566Ba&default-theme=true

RNS Number : 7566B  Haleon PLC  21 March 2025

21 March 2025

HALEON PLC

("Haleon" or "the Company") 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BMX86B70

Issuer Name

HALEON PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Pfizer Inc.

City of registered office (if applicable)

New York

Country of registered office (if applicable)

United States of America

4. Details of the shareholder

 Name                           City of registered office  Country of registered office
 State Street Nominees Limited  London                     United Kingdom

5. Date on which the threshold was crossed or reached

21-Mar-2025

6. Date on which Issuer notified

21-Mar-2025

7. Total positions of person(s) subject to the notification obligation

                                                                            % of voting rights attached to shares (total of 8.A)  % of voting rights through financial instruments (total of 8.B 1 + 8.B 2)  Total of both in % (8.A + 8.B)  Total number of voting rights held in issuer
 Resulting situation on the date on which threshold was crossed or reached  0.000000                                              0.000000                                                                   0.000000                        0
 Position of previous notification (if applicable)                          7.310000                                              0.000000                                                                   7.310000

8. Notified details of the resulting situation on the date on which the
threshold was crossed or reached

8A. Voting rights attached to shares

 Class/Type of shares ISIN code(if possible)  Number of direct voting rights (DTR5.1)  Number of indirect voting rights (DTR5.2.1)  % of direct voting rights (DTR5.1)  % of indirect voting rights (DTR5.2.1)
 Ordinary Shares GB00BMX86B70                                                          0                                                                                0.000000
 Sub Total 8.A                                0                                                                                     0.000000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

 Type of financial instrument  Expiration date  Exercise/conversion period  Number of voting rights that may be acquired if the instrument is  % of voting rights
                                                                            exercised/converted

 Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to
(DTR5.3.1R.(1) (b))

 Type of financial instrument  Expiration date  Exercise/conversion period  Physical or cash settlement  Number of voting rights  % of voting rights

 Sub Total 8.B2

9. Information in relation to the person subject to the notification
obligation

1. Person subject to the notification obligation is not controlled by any
natural person or legal entity and does not control any other undertaking(s)
holding directly or indirectly an interest in the (underlying) issuer.

 Ultimate controlling person  Name of controlled undertaking  % of voting rights if it equals or is higher than the notifiable threshold  % of voting rights through financial instruments if it equals or is higher  Total of both if it equals or is higher than the notifiable threshold
                                                                                                                                          than the notifiable threshold

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

This notification relates to the sale by Pfizer Inc. ("Pfizer") of the
entirety of its residual interest in Haleon plc ("Haleon").

Pfizer sold 617,553,920 Haleon ordinary shares ("Ordinary Shares") pursuant to
a secondary offering announced on 18 March 2025. In connection with the
offering, and in addition to the 617,553,920 Ordinary Shares in the offering,
Pfizer sold 44,155,844 Ordinary Shares to Haleon in an off-market sale in
accordance with the terms of a share purchase deed between Haleon and Pfizer
which was previously approved by Haleon's shareholders.

Pursuant to (i) the offering, and (ii) the off-market sale to Haleon, Pfizer
disposed of its entire residual interest in Haleon of 661,709,764 Ordinary
Shares.

Prior to the completion of (i) the offering, and (ii) the off-market sale to
Haleon, Pfizer held its Haleon Ordinary Shares through State Street Nominees
Limited, which held the legal title to those Ordinary Shares on Pfizer's
behalf.

12. Date of Completion

21-Mar-2025

13. Place Of Completion

New York, USA

 

 

Amanda Mellor, Company Secretary

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  HOLUAVBRVWUOUAR